Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20194 | 0.85 | ENPP2 (0.50) | PTGS2ENPP2 | |
| SCHEMBL7677302 | 0.85 | PTGS2 (0.62) | PTGS2ENPP2KIF11PTGS1 | |
| SCHEMBL10300269 | 0.85 | PTGS2 (0.62) | PTGS2ENPP2KIF11PTGS1 | |
| SCHEMBL2183055 | 0.78 | PTGS2 (0.52) | PTGS2ENPP2PTGS1 | |
| SCHEMBL145847 | 0.78 | NR1H2 (0.45) | — | |
| SCHEMBL8510776 | 0.77 | LMNA (0.50) | ENPP2 | |
| SCHEMBL27491694 | 0.77 | CA2 (0.73) | KIF11 | |
| SCHEMBL29118654 | 0.77 | ENPP2 (0.43) | PTGS2ENPP2PTGS1 | |
| SCHEMBL8507889 | 0.77 | LMNA (0.50) | ENPP2 | |
| SCHEMBL2376239 | 0.77 | ENPP2 (0.72) | PTGS2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | claimed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3830074-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | Intervet International B.V. (NL) | 2021-06-09 | — | — | EP | disclosed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3752150-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SRL (BE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2005060665-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PTGS2 1764/4885ENPP2 766/4885KIF11 4705/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | PTGS2 1816/4885ENPP2 718/4885KIF11 4737/4885 |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | PTGS2 661/4885ENPP2 34/4885KIF11 4637/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | PTGS2 1105/4885ENPP2 71/4885KIF11 4478/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PTGS2 1764/4885ENPP2 766/4885KIF11 4705/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | PTGS2 3634/4885ENPP2 1399/4885KIF11 1340/4885 |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | CTSB, CTSF, CTSZ | PTGS2 2234/4885ENPP2 835/4885KIF11 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.